Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2013

View Archived Issues

Novel antibody-drug conjugate for drug-resistant blood cancer tested in preclinical studies

Gilead Sciences presents further clinical data on Stribild

Scripps Research Institute designs dual JNK3/LRRK2 inhibitor

Effective treatment of pancreatic ductal carcinoma xenografts with CBL-0137

Final results of the IMPACT trial of the TLR9 agonist MGN-1703 reported

Sanofi discovers novel FGFR inhibitors

DBV Technologies completes enrollment in VIPES study of peanut allergy

Researchers present phase II results for famitinib in nasopharyngeal carcinoma

Margetuximab well tolerated and active in phase I solid tumors trial

Secukinumab demonstrates superiority to Enbrel in head-to-head phase III study

Bayer begins phase III trial of BAY-94-9027 in children with hemophilia A

Novartis and Biological E to deliver typhoid and paratyphoid vaccines to developing world

Capricor and Nile Therapeutics sign merger agreement

Bayer discloses new FGFR inhibitors for cancer

Sanofi presents novel cannabinoid CB2 receptor ligands

Santaris Pharma licenses Locked Nucleic Acid technology to RaNA Therapeutics

Researchers in the U.K. patent new agents for bacterial infections

EMA accepts MAA for new insulin glargine biosimilar product

Oramed begins patient enrollment in phase IIa trial of ORMD-0801

La Jolla Pharmaceutical begins dosing in phase II trial of GCS-100 in chronic kidney disease

Scientists at Receptos synthesize novel GLP-1 receptor modulators

Phase II study of C. difficile vaccine initiated in Japan

GSK files supplemental NDAs for combination of dabrafenib and trametinib in metastatic melanoma

Novavax commences phase I trial of A(H7N9) influenza vaccine candidate

AstraZeneca enters oncology collaboration with Cambridge medical research institutions

FDA clears Signum Dermalogix's IND application for SIG-990 in rosacea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...